Baby's hand holding its mother's finger

Newsroom

Latest News

News

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Salt Lake City – August 10, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2022.
News

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

Salt Lake City, July 28, 2022 —Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

Salt Lake City – June 6, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…
News

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth Salt Lake City – May 19, 2022 –Sera Prognostics Inc., The…
News

SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING

SALT LAKE CITY, May 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE “EVERY MOTHER, EVERY BABY” PROJECT

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth SALT LAKE CITY, May 5, 2022 Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused…
News

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10

Salt Lake City, May 2, 2022 —Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

Sera Prognostics announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.
News

Sera Prognostics Reports Fourth Quarter 2021 Financial Results

Salt Lake City – March 29, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…
News

Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting

Salt Lake City, March 18, 2022 —Sera Prognostics Inc., The PregnancyCompany ®  (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today presented…

Stay in Touch